The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding
Abstract
Objective: Traditional nonsteroidal antiinflammatory drugs (NSAIDs) increase the risk of upper gastrointestinal (GI) bleeding/perforation, but the magnitude of this effect for coxibs in the general population and the degree of variability between individual NSAIDs is still under debate. This study was undertaken to assess the risk of upper GI bleeding/perforation among users of individual NSAIDs and to analyze the correlation between this risk and the degree of inhibition of whole blood cyclooxygenase 1 (COX‐1) and COX‐2 in vitro. Methods: We conducted a systematic review of observational studies on NSAIDs and upper GI bleeding/perforation published between 2000 and 2008. We calculated pooled relative risk (RR) estimates of upper GI bleeding/perforation for individual NSAIDs. Additionally, we verified whether the degree of inhibition of whole blood COX‐1 and COX‐2 in vitro by average circulating concentrations predicted the RR of upper GI bleeding/perforation. Results: The RR of upper GI bleeding/perforation was 4.50 (95% confidence interval [95% CI] 3.82–5.31) for traditional NSAIDs and 1.88 (95% CI 0.96–3.71) for coxibs. RRs lower than that for NSAIDs overall were observed for ibuprofen (2.69 [95% CI 2.17–3.33]), rofecoxib (2.12 [95% CI 1.59–2.84]), aceclofenac (1.44 [95% CI 0.65–3.2]), and celecoxib (1.42 [95% CI 0.85–2.37]), while higher RRs were observed for ketorolac (14.54 [95% CI 5.87–36.04]) and piroxicam (9.94 [95% CI 5.99–16.50). Estimated RRs were 5.63 (95% CI 3.83–8.28) for naproxen, 5.57 (95% CI 3.94–7.87) for ketoprofen, 5.40 (95% CI 4.16–7.00) for indomethacin, 4.15 (95% CI 2.59–6.64) for meloxicam, and 3.98 (95% CI 3.36–4.72) for diclofenac. The degree of inhibition of whole blood COX‐1 did not significantly correlate with RR of upper GI bleeding/perforation associated with individual NSAIDs (r 2= 0.34,P= 0.058), but a profound and coincident inhibition (>80%) of both COX isozymes was associated with higher risk. NSAIDs with a long plasma half‐life and with a slow‐release formulation were associated with a greater risk than NSAIDs with a short half‐life. Conclusion: The results of our analysis demonstrate that risk of upper GI bleeding/perforation varies between individual NSAIDs at the doses commonly used in the general population. Drugs that have a long half‐life or slow‐release formulation and/or are associated with profound and coincident inhibition of both COX isozymes are associated with a greater risk of upper GI bleeding/perforation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
The Handbook of Research Synthesis.
Howel, D., Cooper, H., & Hedges, L. V. (1995) · Biometrics · doi:10.2307/2533295 · Cited by 3,642
Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., & Tarnawski, A. S. (1999) · Nature Medicine · doi:10.1038/70995 · Cited by 827
Henry, D., Lim, L. L.-Y., Rodriguez, L. A. G., Gutthann, S. P., Carson, J. L., Griffin, M., Savage, R., Logan, R., Moride, Y., Hawkey, C., et al. (1996) · BMJ · doi:10.1136/bmj.312.7046.1563 · Cited by 827
Hernández-Díaz, S., & Rodríguez, L. A. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2093 · Cited by 716
Self-citationSchnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
Patrono, C., Ciabattoni, G., Pinca, E., Pugliese, F., Castrucci, G., De Salvo, A., Satta, M. A., & Peskar, B. A. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90066-3 · Cited by 651
Mizuno, H., Sakamoto, C., Matsuda, K., Wada, K., Uchida, T., Noguchi, H., Akamatsu, T., & Kasuga, M. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024292 · Cited by 637
Cited by
Use of NSAIDs in treating patients with arthritis
Crofford, L. J. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4174 · Cited by 650
New insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469
Self-citationBrandow, A. M., Carroll, C. P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R. W., Kutlar, A., Seisa, M., Stinson, J., Strouse, J. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001851 · Cited by 456
McGettigan, P., & Henry, D. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001388 · Cited by 414
Conaghan, P. G. (2012) · Rheumatology International · doi:10.1007/s00296-011-2263-6 · Cited by 407
Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis
Oscanoa, T. J., Lizaraso, F., & Carvajal, A. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2225-3 · Cited by 382
Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., Sturkenboom, M., Perez-Gutthann, S., & Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project (2012) · Drug Safety · doi:10.1007/bf03261999 · Cited by 341
Individual NSAIDs and Upper Gastrointestinal Complications
Castellsagué, J., Riera‐Guàrdia, N., Calingaert, B., Varas‐Lorenzo, C., Fourrier‐Réglat, A., Nicotra, F., Sturkenboom, M., & Perez‐Gutthann, S. (2012) · Drug Safety · doi:10.2165/11633470-000000000-00000 · Cited by 309
Non-steroidal anti-inflammatory drugs and the gastrointestinal tract
Tai, F. W. D., & McAlindon, M. E. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0039 · Cited by 285
Bruyère, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J., Luisa Brandi, M., Kanis, J. A., Altman, R. D., Hochberg, M. C., et al. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.11.010 · Cited by 274
Jung, Y.-S., Park, W., Park, H., Lee, D.-K., & Na, K. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.08.068 · Cited by 268
de Abajo, F. J. (2011) · Drugs & Aging · doi:10.2165/11589340-000000000-00000 · Cited by 206
Management of Osteoarthritis: Expert Opinion on NSAIDs
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00260-1 · Cited by 201
Paracetamol – An old drug with new mechanisms of action
Przybyła, G. W., Szychowski, K. A., & Gmiński, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13392 · Cited by 190
Metadata
- Authors
- Massó González, E. L., Patrignani, P., Tacconelli, S., & Rodríguez, L. A. G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-05-28
- Volume
- 62
- Issue
- 6
- Pages
- 1592-1601
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2015698186
- Cited by
- 264
- References
- 38
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.